Workflow
DoorDash Stock Nabs Analyst Upgrade After Sell-Off. Food-Delivery Leader 'Underappreciated.'
Investors· 2025-11-19 23:14
DoorDash股票评级与市场表现 - Jefferies将DoorDash评级从持有上调至买入[1] - 公司第三季度财报后因2026年投资计划警告导致股价下跌[1] - DoorDash宣布与Waymo合作开展机器人食品配送业务[4] 主要科技公司动态 - 英伟达和Alphabet股价上涨推动股市走高[1] - Robinhood、AppLovin和ARM成为财报季关键波动股[1][2] - 特斯拉股东将对埃隆·马斯克1万亿美元薪酬方案进行投票[1][2] 行业与市场概况 - 黄金类股票在最佳股票榜单中占据主导地位[4] - 道琼斯期货因银行股反弹收复失地[4] - 数据中心相关股票获得分析师看好[4]
Larry Summers steps down from OpenAI board over Epstein ties
Fortune· 2025-11-19 23:11
Larry Summers will leave the board of OpenAI, part of his departure from public roles after US lawmakers released the former US Treasury Secretary’s correspondence with the late disgraced sex offender Jeffrey Epstein.“Larry has decided to resign from the OpenAI Board of Directors, and we respect his decision,” OpenAI said in a statement Wednesday. “We appreciate his many contributions and the perspective he brought to the Board.” On Monday, Summers announced he was stepping away from public commitments and ...
MP Materials gets another government deal, this time in Saudi Arabi
MarketWatch· 2025-11-19 23:11
MP Materials' stock was surging Wednesday after the rare-earth producer announced a partnership with the U.S. government to build a refinery in Saudi Arabia. ...
GRNJ: First Look At Tom Lee's New Small/Mid Cap Granny Shots ETF
Seeking Alpha· 2025-11-19 23:11
The Sunday Investor is focused exclusively on U.S. Equity ETFs. He has a strong analytical background, has received a Certificate of Advanced Investment Advice from the Canadian Securities Institute, and has completed all the educational requirements for the Chartered Investment Manager designation.Having covered hundreds of ETFs on Seeking Alpha, The Sunday Investor has developed a complex, proprietary ETF Rankings system which he shares on his website, etf-rankings.com. Nearly 1,000 ETFs receive individua ...
Blockfusion to list in New York via $450 million SPAC deal
Reuters· 2025-11-19 23:11
Data center operator Blockfusion said on Wednesday it would list in the United States through a merger with blank-check firm Blue Acquisition Corp in a deal valued at $450 million, as investor appetit... ...
3 Auto Replacement Parts Stocks to Benefit From Aging Fleet
ZACKS· 2025-11-19 23:10
The Zacks Automotive Replacement Partsindustry is grappling with rising challenges as modern vehicles become increasingly complex, requiring specialized tools and expertise that strain aftermarket suppliers and elevate service costs. Manufacturers also face profitability pressures due to heavy exposure to U.S. import tariffs on parts sourced from China and Europe. However, the industry stands to benefit from the growing average age of vehicles in the United States, which is boosting demand for maintenance a ...
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
ZACKS· 2025-11-19 23:10
2025年第三季度业绩 - 公司于10月31日盘前公布2025年第三季度业绩,营收和盈利均超预期 [1] - 营收同比增长9.1%,但由于收购相关成本,盈利同比下降38% [1] - 公司年内第三次上调2025年营收和每股盈利指引,得益于年初至今的强劲势头 [1] 股票表现与估值 - 业绩公布后股价下跌,可能源于肿瘤药物销售疲软和美学业务持续疲弱,但股价在第三季度下跌后已回升,并于11月12日突破50日移动平均线 [2] - 年初至今股价上涨31.6%,同期行业指数上涨14.2%,表现优于行业、板块和标普500指数 [16][17] - 公司远期市盈率为16.74,低于行业的16.81,但高于其五年均值13.36,与其他大型药企相比估值更具吸引力 [19] - 过去30天内,2025年每股盈利共识预期从11.15美元下调至10.63美元,2026年预期从14.41美元微降至14.39美元 [21][23] 核心免疫学药物表现 - 成功应对Humira专利到期影响,两款新免疫学药物Skyrizi和Rinvoq表现强劲,将驱动未来几年增长 [3] - 2025年前九个月,Skyrizi和Rinvoq合计销售额达185亿美元 [4] - Skyrizi年化销售额近180亿美元,Rinvoq年化销售额超80亿美元,公司预计2025年两款药物合计销售额将超250亿美元目标,2027年将超310亿美元 [5] - Rinvoq通过与所有仿制药制造商达成专利诉讼和解,专利独占期延长四年至2037年 [6] 肿瘤学与神经科学业务 - 肿瘤业务组合(包括Imbruvica和Venclexta)在前九个月产生合计收入50亿美元,同比增长2.7% [7] - 神经科学药物销售额在前九个月增长20.3%,达到近78亿美元,主要由Botox Therapeutic、Vraylar及新偏头痛药物Ubrelvy和Qulipta驱动 [8] - 帕金森病新药Vyalev的初步国际上市表现鼓舞人心,该领域被视为神经科学增长关键 [9][10] 收购活动与产品管线 - 公司过去几年进行超过30笔并购交易,以加强早期管线,特别是在核心的免疫学领域,同时也通过早期联盟进入肿瘤学和神经科学领域 [11] - 近期收购Gilgamesh Pharmaceuticals的bretisilocin,加强了神经科学管线 [11] - 未来几年,公司预计将有新产品获批(如tavapadon, pivekimab sunirine)以及关键管线候选药物的重要数据读出 [10] 面临的主要挑战 - Humira销售额因生物类似药侵蚀持续下滑,2025年前九个月销售额下降超50% [12] - 美学业务单元销售疲软,2025年前九个月全球销售额下降7.4%,公司将2025年该业务预期从51亿美元下调至49亿美元 [13][15] - 宏观经济挑战和低消费者信心,尤其是美国市场,影响可自由支配支出,导致Juvederm和Botox Cosmetics销售额显著下滑 [14] 增长前景与财务政策 - 2025年第三季度,非Humira药物销售额增长超20%,高于预期 [24] - 公司预计2025年将恢复中个位数营收增长,并预计到2029年实现高个位数复合年增长率,主要驱动力为Skyrizi和Rinvoq的强劲表现 [25] - 未来十年无重大专利到期事件,为公司提供了加大研发投入和持续外部创新的灵活性 [25] - 公司近期将季度现金股息提高了5.5% [26]
Firan Technology Is A Speculative Bet On Defense And Airbus' Growth
Seeking Alpha· 2025-11-19 23:10
My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...
Alphabet's stunning stock surge this year could fuel this never-before-seen feat
MarketWatch· 2025-11-19 23:10
公司股价表现 - Alphabet公司股票有望成为其历史上首次年度表现最佳的“七巨头”股票 [1]